Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 01, 2015 5:15 PM ET

Biotechnology

Company Overview of Elan Corporation, plc

Company Overview

Elan Corporation, plc operates as a biotechnology company in the United States, Ireland, and internationally. The company primarily develops ELND005, an orally bioavailable small molecule in Phase II clinical trial being investigated for multiple neuropsychiatric indications on the basis of its proposed dual mechanism of action, which includes b-amyloid anti-aggregation and regulation of brain myo-inositol levels. It also develops ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder to delay the time to occurrence of mood episodes; and for the treatment of agitation/aggression in patients with moderate to severe Alzheimer’s disease. Elan Corporation, plc was fou...

Treasury Building

Lower Grand Canal Street

Dublin,  2

Ireland

Founded in 1969

245 Employees

Phone:

353 1 709 4000

Fax:

353 1 709 4700

Key Executives for Elan Corporation, plc

Elan Corporation, plc does not have any Key Executives recorded.

Elan Corporation, plc Key Developments

Elan Provides Group and Parent Earnings Guidance for the Year 2014

Elan expects to end 2014 with a profit on the back of 3% higher revenues of EUR 70 million ($79 million). Net profit is expected to be achieved both at group level and by the parent company.

Elan Plc Announces Resignation of Gary Kennedy as Director

Elan Corporation plc announced that following the completion of the acquisition by Perrigo Company plc of Elan Corporation plc on 18 December, 2013, Gary Kennedy, Greencore Chairman is no longer a director of Elan plc.

Elan Corporation, plc(ISE:DRX) dropped from S&P EUROPE 350

Elan Corporation, plc(ISE:DRX) dropped from S&P EUROPE 350

Similar Private Companies By Industry

Company Name Region
Elan Corp Ltd. Europe
Alexo Therapeutics Ltd Europe
Nuritas, Ltd. Europe
ViRexx International Corp. Europe
DiaSorin Ireland Ltd Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Elan Corporation, plc, please visit www.elan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.